PL371487A1 - 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors - Google Patents

3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors

Info

Publication number
PL371487A1
PL371487A1 PL03371487A PL37148703A PL371487A1 PL 371487 A1 PL371487 A1 PL 371487A1 PL 03371487 A PL03371487 A PL 03371487A PL 37148703 A PL37148703 A PL 37148703A PL 371487 A1 PL371487 A1 PL 371487A1
Authority
PL
Poland
Prior art keywords
imidazolyl
tafia inhibitors
alkoxypropanoic
acids
alkoxypropanoic acids
Prior art date
Application number
PL03371487A
Other languages
English (en)
Polish (pl)
Inventor
Charlotte Moira Norfor Allerton
David John Bull
Mark Edward Bunnage
Robert John Maguire
John Steele
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0201389A external-priority patent/GB0201389D0/en
Priority claimed from GB0202027A external-priority patent/GB0202027D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of PL371487A1 publication Critical patent/PL371487A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL03371487A 2002-01-22 2003-01-10 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors PL371487A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0201389A GB0201389D0 (en) 2002-01-22 2002-01-22 3-(imidazolyl)-2-alkoxypropanoic acids
GB0202027A GB0202027D0 (en) 2002-01-29 2002-01-29 3-(imidazolyl)-2-alkoxypropanoic acids

Publications (1)

Publication Number Publication Date
PL371487A1 true PL371487A1 (en) 2005-06-13

Family

ID=27614792

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03371487A PL371487A1 (en) 2002-01-22 2003-01-10 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors

Country Status (24)

Country Link
EP (1) EP1467731A1 (is)
JP (1) JP2005520811A (is)
KR (1) KR20040077775A (is)
CN (1) CN1620291A (is)
AP (1) AP2004003084A0 (is)
AR (1) AR038197A1 (is)
BR (1) BR0307016A (is)
CA (1) CA2472238A1 (is)
EA (1) EA200400716A1 (is)
EC (1) ECSP045200A (is)
HR (1) HRP20040659A2 (is)
IL (1) IL162677A0 (is)
IS (1) IS7310A (is)
MA (1) MA27167A1 (is)
MX (1) MXPA04006573A (is)
NO (1) NO20043457L (is)
OA (1) OA12756A (is)
PA (1) PA8563501A1 (is)
PE (1) PE20030929A1 (is)
PL (1) PL371487A1 (is)
TN (1) TNSN04121A1 (is)
TW (1) TW200302094A (is)
UY (1) UY27615A1 (is)
WO (1) WO2003061652A1 (is)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051384A1 (en) * 2003-11-25 2005-06-09 Pfizer Limited Stabilised pharmaceutical compositions
CA2604912A1 (en) * 2005-04-18 2006-10-26 Bayer Schering Pharma Aktiengesellschaft Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci
AU2009310841A1 (en) 2008-10-29 2010-05-06 Taisho Pharmaceutical Co., Ltd. Compounds having TAFIa inhibitory activity
AU2009322342A1 (en) * 2008-12-05 2011-06-30 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXa inhibitors
US8987242B2 (en) 2008-12-05 2015-03-24 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXA inhibitors
KR20130006620A (ko) * 2010-03-18 2013-01-17 다이이찌 산쿄 가부시키가이샤 시클로프로판카르복실산 유도체
SG10201502026XA (en) 2010-03-18 2015-05-28 Daiichi Sankyo Co Ltd Cycloalkyl-substituted imidazole derivative
RU2015156612A (ru) 2013-06-10 2017-07-17 Санофи Макроциклические производные мочевины в качестве ингибиторов tafia, их получение и их применение в качестве фармацевтических средств
US20190117624A1 (en) 2016-03-29 2019-04-25 Daiichi Sankyo Company, Limited Therapeutic agent for inflammatory bowel diseases
MY202326A (en) 2017-09-14 2024-04-24 Daiichi Sankyo Co Ltd Compound having cyclic structure

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
PT1311488E (pt) * 2000-08-17 2009-12-30 Pfizer Ltd Imidazóis substituídos utilizados como inibidores de tafia

Also Published As

Publication number Publication date
IL162677A0 (en) 2005-11-20
UY27615A1 (es) 2003-08-29
IS7310A (is) 2004-06-14
TNSN04121A1 (en) 2006-06-01
KR20040077775A (ko) 2004-09-06
WO2003061652A8 (en) 2004-09-10
TW200302094A (en) 2003-08-01
AP2004003084A0 (en) 2004-09-30
PE20030929A1 (es) 2003-11-05
EP1467731A1 (en) 2004-10-20
MXPA04006573A (es) 2004-10-04
JP2005520811A (ja) 2005-07-14
CN1620291A (zh) 2005-05-25
AR038197A1 (es) 2005-01-05
MA27167A1 (fr) 2005-01-03
BR0307016A (pt) 2004-11-03
HRP20040659A2 (en) 2004-10-31
NO20043457L (no) 2004-08-19
WO2003061652A1 (en) 2003-07-31
CA2472238A1 (en) 2003-07-31
OA12756A (en) 2006-07-03
PA8563501A1 (es) 2004-08-31
ECSP045200A (es) 2004-08-27
EA200400716A1 (ru) 2004-12-30

Similar Documents

Publication Publication Date Title
EG25482A (en) Inhibitors
IL153225A0 (en) Substituted imidazoles as tafia inhibitors
AU2003271566A8 (en) Pyrrolopyrazines as kinase inhibitors
AU2003202263A1 (en) Roh-kinase inhibitors
AU2003278088A1 (en) Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
SI1492785T1 (sl) 2-hidroksi-3-heteroarilindolni derivati kot inhibitorji GSK3
EP1551801A4 (en) NOVEL GAMMA-LACTAMES AS INHIBITORS OF BETA-SECRETASE
PL376021A1 (en) Pyrrolidone derivatives as maob inhibitors
AU2003231872A1 (en) Imidazolium cxcr3 inhibitors
IL178672A0 (en) Imidazole derivatives used as tafia inhibitors
EP1532133A4 (en) NF-: B INHIBITORS
IL162677A0 (en) 3-(Imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
AU2003230392A8 (en) Beta-secretase inhibitors
ZA200409691B (en) Heterotricyclyl 6-alkylidene-penems as ß-lactamase inhibitors
EP1506778A4 (en) TGF-a EXPRESSION INHIBITORS
IL173911A0 (en) Imidazole derivatives
AU2003242559A8 (en) Alkylaminosiloxanes as corrosion inhibitors
IL172821A0 (en) Imidazole derivatives iii
ZA200405344B (en) 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors.
AU2003210671A1 (en) Nek2 inhibitors
AU2003232362A8 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
GB0202027D0 (en) 3-(imidazolyl)-2-alkoxypropanoic acids
GB0201911D0 (en) 3-(Imidazolyl)-2-Aminopropanoic acids
GB0201387D0 (en) 3-(imidazolyl)-2-aminopropanoic acids
IL169094A0 (en) 1-n-phenylamino-1h-imidazole derivatives as aromatase inhibitors